Bapineuzumab trials were the first to show a correlation between Aβ reduction and t-Tau and p-Tau in CSF (NCT00112073) and since t-Tau is correlated with a poor prognosis in brain disorders, as well as the level of p-Tau seems to reflect the NFTs formation in the brain, further investigation was carried out [104]. The gene discussed is MAPT; the disease is brain disorder.